Skip to main content
Premium Trial:

Request an Annual Quote

Prolinx Raises $16.8M in New Financing

NEW YORK, July 17 - Prolinx has raised $16.8 million in new funding, the company announced Tuesday.

The Bothell, Wash.-based manufacturer of tools and applications for manipulating macromolecules said it would use the new funds for product releases, including a protein microarray product line and a series of molecular interaction analysis systems for label-free detection in bioresearch and drug discovery.

"With the evolution of bioresearch and drug discovery towards the analysis of proteins and other complex systems, the demand for Prolinx technologies and products is increasing," Jim Mahoney, CEO of Prolinx, said in a statement. "This funding will allow us to accelerate the release of new products and to invest in the infrastructure required to market, sell, and support these new products."

The latest round of financing included new investors Stephens Group and Wheatley Partners, and existing investors Tullis-Dickerson, BA Venture Partners, Axiom Venture Partners, Technology Funding, Javelin Capital, MDS Ventures Pacific, and Sofinnova Ventures.

Prolinx was founded in 1995.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.